Possibility of "healthy life expectancy 120 years" that has been seen in the development of aging cell removal drugs

As a trump card for aging control, drugs that remove aging cells (Senoritics) are attracting global attention.Among them, it is the Deputy Director of the University of Tokyo Medical Science Research Institute, Professor Makoto Nakanishi, who is the Deputy Director of the University of Tokyo Medical Science, who is developing the world's first aging cell removal drugs, removing different types of aging cells.A research group.Professor Nakanishi is also a program manager for the Moon Shot -type research and development project, which is promoted by the Cabinet Office to create destructive innovation from Japan.We interviewed Professor Nakanishi about the possibility of practical use of aging cell removal drugs and the purpose of promoting aging research.

東京大学医科学研究所副所長・癌防御シグナル分野の中西真教授（写真：川田 雅宏、以下同）［画像のクリックで別ページへ］

Gls1 (Glutaminase 1) inhibitors, which are also attracting worldwide new drug candidates for removing different types of aging cells into one -off, are GLS1 (Glutaminase 1) inhibitors."One of the major factors in aging is that aging cells that cause chronic inflammation accumulate in the organs and tissues. In fact, it is very diverse, even if it is a bite, but after the cell division is stopped.It is common to survive in the living body. We have found that the enzyme named GLS1 is the surviving a wide variety of aging cells among the individuals.Professor Nakanishi explains that the GLS1 inhibitor is blocked by blocking cell death and removing aging cells.

In a human being, a study that analyzes the changes three times a month in the old -age mouse, which is equivalent to the 70s, is analyzed in the abdominal cavity three times a week and analyzes the change one month later, shows the renal function as aging.The function of each organs has been improved, reducing lung fibrosis, liver inflammation, etc.Usually, when aging cells accumulate, inflammation, such as TNF-α (tumor necrotic factor α) and IL-6 (interloykin 6), increases in the blood.However, when GLS1 inhibitors were administered to the old-age mouse, the TNF-α and IL-6 in the blood became about the same as the young mice, and a remarkable improvement of arteriosclerosis due to obesity was seen ( * 1).

"As the mouse and humans become older, muscle mass decreases, motor capacity such as grip strength decreases, and fat tissue atrophy causes metabolic abnormalities.It turns out that a decrease in grip and the atrophy of the fat tissue can be suppressed. When the mouse is hung on a stick and the athletic ability and grip strength are seen, ordinary old mice fall out of the stick in about 30 seconds.On the other hand, if the GLS1 inhibitor is administered, it will be possible to continue hanging on average about 100 seconds on average. If you compare it to a human, it should be in the 70s and 80s, but the grip strength has rejuvenated until about 40 to 50s.Professor Nakanishi says.

図1●GLS1阻害剤による老化・老年病の改善中西教授らによるマウスを使った実験によれば、グルタミン代謝を標的とした阻害剤は老化細胞除去の作用を有し、加齢現象や老年病、生活習慣病の症状を改善することが分かった（出所：「老化細胞を除去して健康寿命を延伸する」、以下注記のない資料は同）［画像のクリックで別ページへ］